Discovery of a Novel Silybin Derivative for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

MASH has become the leading cause of liver disease worldwide, and the prevalence of MASH is steadily increasing. The development of new drugs for the treatment of MASH is urgent. Silybin has been used for decades in liver protection, but its insufficient antioxidant capacity and poor oral bioavailab...

Full description

Saved in:

Bibliographic Details
Main Author:	Zhongtai Sui (19434949) (author)
Other Authors:	Mo Li (43239) (author), Xueyi Wang (335442) (author), Cailin Luo (19434952) (author), Ling Chen (25698) (author), Xu Deng (1688152) (author), Mingjian Li (10132592) (author), Li Liu (75607) (author), Xinyu Huang (679541) (author), Xinyu Zhu (579718) (author), Caiyun Nie (9947756) (author), Shuang Ni (47931) (author), Junfeng Ye (9027869) (author), Shuhang Peng (21520199) (author), Bo Peng (273834) (author), Zhengying Ma (21520202) (author), Zhiyong Luo (2392747) (author), Suyou Liu (2407630) (author), Dayou Ma (16953860) (author)
Published:	2025
Subjects:	Biochemistry Cell Biology Neuroscience Pharmacology Biotechnology Immunology Cancer Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified showed excellent activity poor oral bioavailability insufficient antioxidant capacity inhibiting lipid accumulation good safety profile good oral bioavailability novel silybin derivative liver disease worldwide associated steatohepatitis mash a2 </ b steadily increasing significantly ameliorated promising candidate potent agent pathological features new drugs metabolic dysfunction liver protection leading cause findings demonstrated clinical use
Tags:	Add Tag No Tags, Be the first to tag this record!

Discovery of a Novel Silybin Derivative for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Similar Items